There are currently 75 ongoing clinical trials involving Ocular Melanoma
Of the 75 trials,24 trials are in Phase II
Furthermore, 21 trials are in Phase I/II
The global pharmaceutical industry is steadily developing new drugs for Ocular Melanoma, an Oncology condition. The largest number of ongoing clinical trials for Ocular Melanoma is conducted in North America. Asia-Pacific and Europe are among some of the other prominent regions engaged in Ocular Melanoma-related drug trials.
University of Texas MD Anderson Cancer Center: The leading ongoing Ocular Melanoma related clinical trial sponsor
University of Texas MD Anderson Cancer Center is the top sponsor for Ocular Melanoma-related ongoing clinical trials.
Herbert Irving Comprehensive Cancer Center, Thomas Jefferson University Hospitals, Columbia University and University of Virginia are among other notable clinical trial sponsors involved in Ocular Melanoma. A clinical trial sponsor can be a Company, Government, Individual, or Institution.
Marketed Drugs involving Ocular Melanoma
Ofloxacin (Oraloxin, Oraloxcin) is a key marketed drug involving Ocular Melanoma.
Ofloxacin (Oraloxin, Oraloxcin) is an antibacterial agent. It functions via DNA Gyrase (EC 5.99.1.3) Inhibitor; DNA Topoisomerase IV (EC 5.99.1.3) Inhibitor mechanism of action. Ofloxacin is formulated as film coated tablets for oral route and solution for ophthalmic route of administration. Ofloxacin was first approved in 2014 and is marketed solely in South Korea by Hutecs Co Ltd.
United States of America
China
Switzerland
United States of America
United States of America
United States of America
United States of America
Germany
France
Switzerland
Don’t wait - discover a universe of connected data & insights with your next search. Browse over 28M data points across 22 industries.
Access more premium companies when you subscribe to Explorer